Report
TheScreener
EUR 13.26 For Business Accounts Only

BB BIOTECH AG sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to BB BIOTECH AG (CH), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date March 4, 2022, the closing price was CHF 61.95 and its target price was estimated at CHF 58.85.
05/03/2022 1 EN
Underlying
BB Biotech AG
BB Biotech AG

Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.

See profile
CH0038389992 Six Swiss Exchange Switzerland
Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded. 

 

See profile
Other Reports on these Companies
Other Reports from TheScreener
Read more reports

ResearchPool Subscriptions

Get the most out of your insights

Get in touch